Needham & Company initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Buy. PT $57.00.

Analyst Chad Messer comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE